Figure 2From: Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells Drug release profiles of tyrphostin AG-1478 from from NLC-C and NLC-D samples in human plasma at 37 ± 0.1°C, expressed as percentage wt% of released drug as a function of incubation time. Each value is the mean of three experiments.Back to article page